Lockheed Martin Corp. (NYSE: LMT) — Investment Research Report (Sep 27, 2025)

1) Company Overview & Business Model

Lockheed Martin (“LMT”) is a global prime contractor focused on advanced defense, aerospace, and security systems. Operations are organized into four segments: Aeronautics, Missiles & Fire Control (MFC), Rotary & Mission Systems (RMS), and Space. The company’s model emphasizes multi-year, often cost-plus or fixed-price development and production programs, followed by long tails of sustainment, upgrades, and services across a largely government customer base (U.S. DoD and allied nations). 2024 net sales were $71.0B, and the year-end backlog was $176B; by Q2’25 backlog rose to $166.5B (after burn and new awards).

Recent results & mix (high level). Q1’25 sales were $18.0B (EPS $7.28); Q2’25 sales were $18.2B but GAAP EPS fell to $1.46 on $1.6B program charges tied to a classified Aeronautics effort and certain Sikorsky programs.

2) Strengths

• Scale, incumbency, & portfolio depth. LMT is the largest pure-play defense prime by sales with entrenched positions on flagship programs (e.g., F-35 fighter, missile defense, Aegis/Radar, space systems). This incumbency sustains bargaining power and follow-on work (mods/sustainment).
• Massive, visible backlog. Backlog of $166.5B at Q2’25 underpins multi-year revenue visibility across segments and geographies.
• Diversified customer base & programs. ~26% of 2024 sales were international; allied demand (Europe/Asia) supports F-35, missiles, and sensors.
• Contract wins & program momentum. Sikorsky (RMS) secured an ≈$11B U.S. Navy CH-53K contract (up to 99 aircraft; 2029–2034 deliveries), reinforcing long-tail production and sustainment economics.
• Cash returns & dividend durability. LMT declared a quarterly dividend of $3.30/share in 2025 (22-year raise streak), reflecting strong capital return discipline.

3) Weaknesses

• Program execution variability. Q2’25 featured a $1.6B pre-tax charge on a classified program and Sikorsky helicopters, driving ~80% YoY profit decline that overshadowed otherwise steady sales. Execution lapses can cause volatility in GAAP earnings and cash.
• F-35 specific headwinds. TR-3 software/hardware upgrade delays constrained deliveries and triggered withholdings by the Pentagon; despite progress, milestone shifts and budget adjustments can affect near-term mix and cash.
• Working-capital & fixed-price exposure. Inflation/supply chain challenges persist on older fixed-price development/production lots across industry, increasing risk of negative margins if costs overrun. (Context from Q2’25 coverage.)
• Book value optics. Extensive buybacks and accounting (pension, intangibles) make book equity small, yielding a high P/B metric that is less meaningful for valuation but optically “expensive.”

4) Risks (Categorization & Impact)

• Regulatory/Budget Risk (High). U.S. defense spending and appropriations (including continuing resolutions) drive order timing. Delays or shifts in program priorities (e.g., fighter procurement profiles, missile defense allocations) can deflate near-term growth. (Budget/appropriations context implicit in company reporting.)
• Program Execution & Contract Type (High). Development programs—especially fixed-price—carry cost-overrun and schedule risk (evidenced by Q2’25 charges). Impact: earnings volatility, margin compression, potential negative FCF in affected periods.
• Competition (Medium). RTX, Northrop Grumman, General Dynamics, and Boeing Defense compete on key franchises (missile defense, space, C2/sensors). Impact: pricing pressure in recompetes; share shifts in next-gen programs.
• Supply Chain/Inflation (Medium). Long-lead materials and labor constraints can pressure schedules and raise input costs on legacy contracts. Impact: margin headwinds and cash timing risk. (Industry trend referenced in Q2 reporting.)
• Geopolitical/Export Controls (Medium). While conflict elevates demand, export approvals and ITAR controls can delay international awards. Impact: backlog conversion timing.

5) Competitors & Competitive Landscape

Primary peers: Northrop Grumman (NOC), RTX (Raytheon), General Dynamics (GD), with smaller Boeing Defense as a key competitor on selective programs. NOC and GD trade at ~22x and ~22x P/E, respectively (TTM), while LMT’s P/E’s prints between ~17x (Macrotrends TTM) and ~27x (Yahoo trailing) depending on charge treatments and time windows; RTX skews larger on sales but more commercial aero exposure.

Differentiation: LMT’s edge is breadth of programs, especially F-35 (air superiority franchise with multi-decade sustainment), layered air/missile defense, and growing Space segment. Peers differentiate with strategic niches: NOC (GBSD/ICBM replacement, stealth bombers, space), RTX (missiles/sensors; large commercial aerospace exposure), GD (combat systems, IT/mission systems).

6) Growth Potential

• Historical growth: 2024 net sales +5% YoY to $71.0B; FCF $5.3B. Q1’25 grew YoY; Q2’25 sales were slightly above Q2’24 despite charges.
• Near/Mid-term drivers (12–36 mo):
  • Backlog conversion (>$160B) across all segments.
  • F-35 TR-3 normalization → delivery cadence and cash withhold release.
  • Missile defense & munitions replenishment (PAC-3, HIMARS/PrSM, LRASM/JASSM production) amid elevated geopolitical demand. (Program families detailed in segment disclosures.)
  • Space growth (missile warning/tracking, OPIR, hypersonic defense, classified payloads). (Company 2024/2025 materials.)
  • Rotary recovery via large awards (e.g., CH-53K multiyear), plus sustainment.
• M&A / Acquisition target? LMT’s scale ($110B+ market cap) and strategic importance make it an unlikely acquisition target; anti-trust and national security considerations preclude a take-out. More likely: bolt-ons or JV partnerships aligned to hypersonics, space sensors, and C2.

Note: “Loan growth” is not applicable to a defense prime.

7) Valuation

Relative (as of late Sep 2025)

Differences reflect charge-heavy GAAP vs. alternative trailing windows/adjusted views. Sources: Macrotrends, Yahoo Finance.

Takeaway: On sales, LMT trades at a modest premium to long-term historical averages but within defense-prime norms. P/E looks mixed due to 2025 charges (GAAP), while P/B is not diagnostic for buyback-heavy primes with small book equity.

Absolute (Earnings-Power approach)

• Base earnings power: Use 2024 GAAP EPS $22.31 as conservative mid-cycle anchor; acknowledge 2025 GAAP distortion from Q2 charges.
• Quality multiple: Given backlog visibility, diversified program base, and solid FCF, a 18–22× mid-cycle multiple is reasonable (below tech-like multiples, above cyclicals).
• Intrinsic value range: $400–$490 (18–22× on ~$22–$22.5 EPS). If TR-3 normalized and margins stabilize, an upside case at 24× on ~$23–$24 EPS implies $550–$575. Downside case at 16× on $22 implies ~$350.

Valuation conclusion: Shares screen around fair value to slightly rich versus our base range, with upside dependent on execution clean-up (F-35/TR-3) and continued award flow (e.g., Sikorsky, missile defense, space).

8) Overall Quality Conclusion

LMT remains a tier-one, high-quality defense franchise with exceptional program breadth, durable customer ties, and multi-year visibility (>$160B backlog). 2025’s charge-related EPS volatility highlights the execution risk inherent in large, complex programs, but doesn’t negate the long-term cash-flow story. Net: above-average quality with good long-term compounding potential, tempered near-term by program clean-up and delivery cadence normalization.

9) Investment & Trading Strategy (Actionable)

Rating: HOLD (Accumulate on pullbacks).

Rationale: Strategic positioning + backlog strength support mid-cycle value; however, GAAP noise and program risk warrant patience on adds.

Entry strategy (investors):

• Staggered buys on pullbacks of ~8–12% from current levels (volatility around program headlines/budget cycles is common in primes).
• Alternatively, tie adds to execution milestones (e.g., formal TR-3 delivery cadence recovery; major award conversions into funded backlog).

Targets / Exit:

• Base 12–18 mo target: $520–$540 (implies ~22–23× normalized $23–$24 EPS as charges fade).
• Trim/reevaluate: $550–$575 if multiple expands ahead of clearer EPS normalization.

Risk management (traders):

• Initial stop-loss: ~7–10% below entry to respect event-risk volatility.
• Position sizing: Scale 1/3–1/2 initially; add on confirmation of positive catalysts.

Time horizon:

• Investors: Medium to long term (12–36 months) for backlog conversion and margin normalization.
• Traders: 2–6 months around earnings/budget catalysts.

Key Catalysts (up/down):

• Up:
  • Clean F-35 TR-3 delivery cadence; release of withheld cash.
  • Large awards & multiyear contracts (e.g., Sikorsky CH-53K production lots, missile defense, space payloads).
  • Budget tailwinds / supplemental appropriations (missiles/munitions replenishment).
• Down:
  • Additional program charges or fixed-price overruns.
  • Procurement deferrals/volume reductions in fighter or missile programs.
  • Prolonged CRs delaying new starts or funding increments.

This report is for information only and not investment advice. Consider objectives and risk tolerance before acting.